Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy

TY - JOUR

T1 - Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy

AU - van Wijk, J.P.

AU - Hoepelman, A.I.

AU - de Koning, E.

AU - Dallinga-Thie, G.

AU - Rabelink, T.J.

AU - Cabezas, M.C.

N1 - Reporting year: 2010 Metis note: ATVBAHA.110.216192 [pii]

PY - 2010

Y1 - 2010

N2 - OBJECTIVE: To compare the effects of rosiglitazone (8 mg/d, n=19) and metformin (2 g/d, n=18) on postprandial lipemia in patients with HIV-lipodystrophy. METHODS AND RESULTS: Lipodystrophy in HIV is associated with insulin resistance and disturbed postprandial triglyceride and free fatty acid (FFA) metabolism. We conducted an open randomized 6-month study with standardized 10-h oral fat-loading tests at baseline and after treatment. Rosiglitazone (-34%) and metformin (-37%) reduced homeostasis model assessment similarly (P

AB - OBJECTIVE: To compare the effects of rosiglitazone (8 mg/d, n=19) and metformin (2 g/d, n=18) on postprandial lipemia in patients with HIV-lipodystrophy. METHODS AND RESULTS: Lipodystrophy in HIV is associated with insulin resistance and disturbed postprandial triglyceride and free fatty acid (FFA) metabolism. We conducted an open randomized 6-month study with standardized 10-h oral fat-loading tests at baseline and after treatment. Rosiglitazone (-34%) and metformin (-37%) reduced homeostasis model assessment similarly (P

U2 - 10.1161/ATVBAHA.110.216192

DO - 10.1161/ATVBAHA.110.216192

M3 - Article

SN - 1079-5642

VL - 31

SP - 228

EP - 233

JO - Artheriosclerosis, Thrombosis and Vascular Biology

JF - Artheriosclerosis, Thrombosis and Vascular Biology

IS - 1

ER -